- Home
- CSTL vs NGL Comparison
CSTL vs NGL Comparison
Compare CSTL & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- NGL
- Stock Information
- Founded
- CSTL 2007
- NGL 1940
- Country
- CSTL United States
- NGL United States
- Employees
- CSTL N/A
- NGL N/A
- Industry
- CSTL Medical Specialities
- NGL Natural Gas Distribution
- Sector
- CSTL Health Care
- NGL Utilities
- Exchange
- CSTL Nasdaq
- NGL Nasdaq
- Market Cap
- CSTL 456.2M
- NGL 446.2M
- IPO Year
- CSTL 2019
- NGL 2011
- Fundamental
- Price
- CSTL $20.30
- NGL $4.27
- Analyst Decision
- CSTL Strong Buy
- NGL
- Analyst Count
- CSTL 6
- NGL 0
- Target Price
- CSTL $37.67
- NGL N/A
- AVG Volume (30 Days)
- CSTL 451.0K
- NGL 565.6K
- Earning Date
- CSTL 08-04-2025
- NGL 08-07-2025
- Dividend Yield
- CSTL N/A
- NGL N/A
- EPS Growth
- CSTL N/A
- NGL N/A
- EPS
- CSTL N/A
- NGL N/A
- Revenue
- CSTL $347,083,000.00
- NGL $3,469,186,000.00
- Revenue This Year
- CSTL N/A
- NGL $6.11
- Revenue Next Year
- CSTL $1.36
- NGL N/A
- P/E Ratio
- CSTL N/A
- NGL N/A
- Revenue Growth
- CSTL 38.43
- NGL N/A
- 52 Week Low
- CSTL $15.45
- NGL $2.64
- 52 Week High
- CSTL $35.84
- NGL $5.73
- Technical
- Relative Strength Index (RSI)
- CSTL 66.24
- NGL 58.36
- Support Level
- CSTL $18.18
- NGL $4.20
- Resistance Level
- CSTL $20.63
- NGL $4.42
- Average True Range (ATR)
- CSTL 0.78
- NGL 0.23
- MACD
- CSTL 0.15
- NGL -0.04
- Stochastic Oscillator
- CSTL 87.97
- NGL 21.97
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.